Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
EPIC: BBH
Market: LSE
52-week High/Low: 123.75p / 102.36p
Sector: Investment Services
Market Cap: 302.02M
BB Healthcare Trust PLC

BB Healthcare Trust PLC

BB Healthcare Trust is a high conviction, unconstrained, long-only vehicle invested in global healthcare equities with a max of 35 stocks. The target annual dividend is 3.5% of NAV and the fund offers an annual redemption option. BB Healthcare is managed by the healthcare investment trust team at Bellevue Asset Management, which also manages BB Biotech.

BB Healthcare Trust PLC

www.bbhealthcaretrust.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in BB Healthcare Trust PLC


BB Healthcare Trust PLC Snapshot

BB Healthcare Trust plc is a high conviction, long-only investment trust invested in listed or quoted global healthcare equities. It is unconstrained and able to invest regardless of market cap, sub sector or region, and the portfolio is concentrated with a maximum of 35 holdings. The target total dividend in the first financial period is 3.5 pence per ordinary share (to be paid mostly out of capital) and in subsequent financial years will be set at 3.5 per cent. of net asset value at the end of the preceding financial year (to be paid mostly out of capital). BB Healthcare has an annual redemption option in order to assist with discount control and directors’ fees (for UK-based directors) are paid in shares. BB Healthcare is managed by Bellevue Asset Management AG which has built a successful track record in this sector.

INVESTMENT OBJECTIVE AND RETURN OBJECTIVES

The investment objective of BB Healthcare is to provide Shareholders with capital growth and income over the long term, through investment in listed or quoted global healthcare companies. BB Healthcare’s specific return objectives are:

  • to beat the total return of the MSCI World Healthcare Index (in sterling) on a rolling 3 year period (the index total return including dividends reinvested on a net basis); and
  • to seek to generate a double-digit total shareholder return per annum over a rolling 3 year period.

INVESTMENT PROCESS

The portfolio comprises a single pool of investments, selected for their 3 to 5 year total return potential. Organic dividend yield is not a consideration in portfolio decisions and the focus is on maximisation of total shareholder return. Stocks are only considered for inclusion in the portfolio following a comprehensive multi-stage due diligence process. The  investment process is based on bottom-up fundamental analysis. Whilst the hypothetical investable universe is very broad, the requirements around levels of daily liquidity and financial disclosure mean that the realistic investable universe is typically approximately 800 stocks at any given time. Companies in the portfolio are selected on the basis of their merits rather than their weighting in any particular benchmark or index.

The investment process can be summarised as consisting of four broad stages:

MACRO CONSIDERATIONS (THEMATIC ASSESSMENT)

These include analysis of sub-sectors within the healthcare industry, including their relative valuations, growth prospects and regulatory outlook. Also, the risks and opportunities associated with the political environment and sector M&A activity. The Portfolio Manager is happy to discount ownership of certain healthcare sub-sectors for multi-year periods based on this analysis.

BOTTOM-UP ANALYSIS (IDEA GENERATION)

This includes the use of proprietary screening tools to narrow the investable universe to the most promising candidates. Management quality and accessibility are key criteria.

SELECTION OF HIGH CONVICTION CORE PORTFOLIO (STOCK WEIGHTING CONSIDERATIONS)

This is driven by the Portfolio Manager’s fundamental analysis of the narrowed investable universe, including the relative attractiveness of sub-sectors, expected returns, downside risk and trading liquidity in potential investee company securities.

RISK MANAGEMENT FRAMEWORK (INDEPENDENT OVERSIGHT)

This is provided by a combination of the Portfolio Manager’s own risk management tools and the oversight provided by a highly experienced, independent Board of non-executive directors. An integral part of this framework is a rigorous selling discipline in relation to portfolio holdings, with position prices and valuations continuously monitored against the Portfolio Manager’s views on valuations and expected returns.

 

Investment Strategy Portfolio

 

TOP 10 HOLDINGS AS AT JUNE 30 , 2017

Align Technology 7.4%
Anthem 6.2%
Walgreens Boots Alliance 5.3%
Amgen 5.2%
Eli Lilly 5.0%
Celgene 4.7%
Intuitive Surgical 4.5%
Shire 4.1%
Illumina 4.0%
Amerisourcebergen 3.9%

 

 

SUB SECTOR BREAKDOWN AS AT JUNE 30, 2017

Biotech 25.8%
Medtech 24.1%
Specialty Pharma 14.6%
Pharma 11.5%
Managed Care 7.4%
Diagnostics 5.5%
Other Healthcare 5.1%
Distributors 3.7%
Facilities 2.2%

 

MARKET CAP BREAKDOWN AS AT JUNE 30, 2017

Mega Cap 34.2%
Mid Cap 33.9%
Small Cap 9.9%
Large Cap 22.0%

 

 

GEOGRAPHICAL BREAKDOWN (OPERATIONAL HQ) AS AT JUNE 30, 2017

United States 92.0%
UK 2.8%
Europe (ex UK) 3.6%
Japan  1.6%

 

BOARD OF DIRECTORS 

PROF. JUSTIN STEBBING, CHAIRMAN

Justin is a clinical oncologist and has published over 500 peer-reviewed papers on cancer. He is a Fellow of the Royal College of Physicians, the American Board of Internal Medicine and the Royal College of Pathologists and sits on a number of advisory boards. He also has previous investment management experience as a healthcare analyst.

JOSEPHINE DIXON, CHAIR OF THE AUDIT COMMITTEE

Josephine is a chartered accountant who sits on the boards of Standard Life Equity Income Trust plc, JP Morgan European Investment Trust plc, Strategic Equity Capital plc and F&C Global Smaller Companies Trust plc. Her executive experience includes finance, governance and general commercial roles in a number of sectors.

RANDEEP GREWAL, CHAIR OF MANAGEMENT ENGAGEMENT COMMITTEE

Randeep is a London-based fund manager at Trium, with over 17 years of Healthcare investment experience, including F&C Asset Management, ICAP Equities and Tudor. Randeep trained as a Vascular and General Surgeon and read both Medicine and Computer Science at Cambridge University. He sits on the board of Tissue Regenix.

PAUL SOUTHGATE

Paul is a London-based managing partner at Eisenstat Capital Partners (ECAP), with 20 years’ investment experience. Before joining ECAP, he managed European equity portfolios at Fortress Investment Group. Prior to that, he was a portfolio manager at Deephaven Capital Management. He began his investment career as an analyst and assistant portfolio manager with UBS Asset Management.

SIDDARTHA MUKHERJEE

Siddhartha is a cancer physician and professor at Columbia University. In addition to his extensive academic publications, he has written several books, including The Emperor of All Maladies (winner of a Pulitzer Prize in 2011). He is a Rhodes scholar and graduated from Stanford University, University of Oxford, and Harvard.

 

INVESTMENT TEAM

Dr. Daniel Koller

Daniel has over 16 years of experience in the healthcare sector. He joined Bellevue Asset Management AG in 2004 and was appointed head of portfolio management for the investment company BB Biotech in 2010. Previously, he was an asset manager for equity4life Asset Management Ltd and prior to that an equity analyst at UBS Warburg, covering the biotechnology sector. Daniel has a PhD in Biotechnology from the Swiss Federal Institute of Technology (ETH) Zurich.

Paul Major

Paul has 18 years of experience in the healthcare sector on the sell-side and was top-rated by a number of institutional investment clients. He was one of the first research partners at Redburn, Europe’s leading independent research firm. His work there included bespoke projects on healthcare portfolio construction for several institutions. Paul was previously an analyst and corporate financier at UBS Warburg and studied biochemistry.

BELLEVUE ADVISORS LIMITED

Claude Mikkelsen
32 London Bridge Street
25th Floor
SE1 9SG London

Phone: +44 (0)203 326 29 83
E-Mail: cmi(at)bellevue.ch

PEEL HUNT LLP (SPONSOR, BROKER, PLACING AGENT & INTERMEDIARIES OFFER ADVISER)

Luke Simpson (Corporate Broking)

Mark Thompson, Eddie Nissen (Sales)

Kathy Boate (Intermediaries)

Moor House

120 London Wall

EC2Y 5ET London

Phone: +44 (0)207 418 89 00

 

MAITLAND (MEDIA ENQUIRIES)

William Clutterbuck/ Georgia Lewis

125 Shaftesbury Avenue

WC2H 8AD London

Phone: +44 (0)201 737 951 51

E-Mail: glewis(at)maitland.co.uk or wclutterbuck(at)maitland.co.uk

BB Healthcare Trust PLC Timeline

Market Reports Including BBH

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use